Malin
Executives
View the org chart displaying its 7 main executives
Most searched biographies at Malin
- Jean-Michel Cosséry, Independent Non-Executive Director
- Rudy Mareel, Lead Independent Non-Executive Director
- Kirsten Drejer, Independent Non-Executive Director
Popular executive movements at Malin
- Darragh Lyons, who is Chief Executive Officer and Director will soon leave the company (posted on August 4 2023).
- Fiona Dunlevy who is Company Secretary, will become Executive Director on Oct. 2, 2023 (posted on August 4 2023).
- Liam Daniel who was Non-Executive Chairman of the Board, becomes Chief Executive Officer (posted on August 4 2023).
Create your alert
to follow the executive moves at Malin.
Market Research
Malin has 338 competitors including Afiniti (United States (USA)), Alida (United Kingdom (UK)) and ABI Research (United States (USA)).
Popular M&A news in Market Research
- Sensor Tower has acquired Data.ai (posted on March 22 2024).
- Accenture has acquired GemSeek (posted on February 21 2024).
- The new name of Sago is Sago. (posted on April 10 2023).
Popular contacts in Market Research
News
Press releases by Malin
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology | Poseida Therapeutics, Inc.
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology : Malin PLC
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma | Poseida Therapeutics, Inc.
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma : Malin PLC
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma | Poseida Therapeutics, Inc.
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 : Malin PLC
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma : Malin PLC
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 | Poseida Therapeutics, Inc.
- CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer : Malin PLC
- View more press releases Close
Social media about Malin
- Malin on Wikipedia, Google News & Yahoo Finance
- Malin on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Kirsten Drejer 
